GlassScriptPhysician profile
Frank A Bartucci
NPI 1336621754
$7,471.49
in general payments reported to CMS, 2019-2025
51 companies · $3,662 in 2025
The $3,662 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,967 · 2022: $1,566 · 2023: $264 · 2024: $13.47 · 2025: $3,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,857 · Education: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,857.39 |
| Education | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,599.36 | 2021-2025 | Octrode, Proclaim |
| Abbvie INC. | $561.87 | 2022-2025 | |
| Ucb, INC. | $471.18 | 2024-2025 | Briviact, Rystiggo |
| Nevro Corp. | $389.77 | 2021-2023 | Senza |
| Biogen, INC. | $322.00 | 2025 | Vumerity, Tysabri, Spinraza |
| Lilly USA, LLC | $288.99 | 2025 | Kisunla |
| Eisai INC. | $271.26 | 2025 | |
| Scilex Pharmaceuticals INC. | $249.35 | 2021-2023 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $244.07 | 2025 | Austedo Xr, Ajovy |
| Vertos Medical, INC. | $241.80 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $208.94 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $169.48 | 2025 | |
| Genentech USA, INC. | $169.20 | 2025 | Ocrevus Zunovo |
| Lundbeck LLC | $148.60 | 2025 | Vyepti, Rexulti |
| Pfizer INC. | $139.11 | 2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Bartucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.